Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Medifast (MED) Defended at DA Davidson
November 7, 2018 9:53 AM ESTDA Davidson analyst Linda Bolton Weiser reiterated a Buy rating and $249 price target on Medifast (NYSE: MED) telling clients to buy on today's pull-back.
Weiser commented, "MED reported 3Q18 sales of $139M, above consensus of $125M and guidance of $120M-$125M. Revenue growth... More
